Preparation, Antibacterial Potential, and Antibacterial Components of Fermented Compound Chinese Medicine Feed Additives

Wanjie Zou 1, Honglan Huang 2, Huadong Wu 3, Yuandong Cao 4, Wei Lu 1* and Yuyong He 1*

1 Jiangxi Province Key Laboratory of Animal Nutrition/Engineering Research Center of Feed Development, Jiangxi Agricultural University, Nanchang, China, 2 Forest Institution, Jiangxi Environmental Engineering Vocational College, Ganzhou, China, 3 College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China, 4 Department of Technology, Jiangxi Jiabo Bioengineering Co. Ltd., Jiujiang, China

This experiment was conducted to compare the antibacterial ability and to identify the antibacterial components of different fermented compound Chinese medicine feed additives in order to develop one fermented compound Chinese medicine feed additive product that can effectively alleviate metritis, vaginitis, and mastitis of sows. The Oxford cup method and double dilution method were used to compare the antibacterial ability of three fermented compound Chinese medicine feed additives (A, B, and C). UHPLC-QE-MS-based untargeted metabolomics was used to identify the antibacterial components of fermented compound Chinese medicine feed additives. Results showed that among fermented compound Chinese medicine feed additives A, B, and C, additive A had the strongest ability to inhibit the growth of Staphylococcus aureus, Salmonella cholerae suis, Escherichia coli, and Streptococcus agalactiae. The MIC and MBC of additive A were the lowest for Staphylococcus aureus compared to that for the other three pathogens. The concentrations of 23 Chinese medicine ingredients (ellagic acid, guanine, camphor, L-valine, sinapine, dipropyl phthalate, 3-hydroxy-5-isopropylidene-3,8-dimethyl-2,3,3a,4,5,8a-hexahydro-6(1H)-azulenone, 7-dihydroxy-2-(4-hydroxyphenyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-6-(3,4,5-trihydroxyoxan-2-yl)chromen-4-one, acetylcholine, farerol, pyrogallol, ethyl gallate, demethylwedelolactone, methyl gallate, kaempferide, gallic acid, eriodictyol, threonic acid, inositol, 3′,4′,7-trihydroxyflavanone, taxifolin, asiatic acid, and isorhamnetin) in additive A were significantly (p < 0.05 or p < 0.01) higher than those in additive B, respectively. It is concluded that the mixture composed of 23 active components in fermented compound Chinese medicine feed additive A plays an important role in inhibiting the growth of Staphylococcus aureus, Salmonella cholerae suis, Escherichia coli, and Streptococcus agalactiae.

Keywords: Chinese medicine feed additive, fermentation, in vitro antibacterial activity, UHPLC-QE-MS based untargeted metabolomics, metabolic network
INTRODUCTION

Metritis, vaginitis, and mastitis of sows can cause a decrease in the number of pigs weaned per sow per year (PSY), because an unstable implantation of fertilized eggs developed by the chronic uteritis and vaginitis of sows will increase embryo death, block fetal intrauterine development, or bring conception into failure (1). Milk produced by sows with mastitis will decrease the survival rate and growth rate of suckling piglets by the increased diarrhea of suckling piglets (2). In the practice of treating metritis, vaginitis, and mastitis of sows over the past decades, in-feed antibiotics and intramuscular injection of antibiotics are often used (3, 4), but since July 1, 2020, the addition of antibiotics to feed is banned in China. Therefore, how to develop Chinese medicine feed additive products instead of antibiotics to control the bacterial pathogens of sows and improve sow’s immunity is of great significance for the improvement of PSY. Previous studies indicated that metritis, vaginitis, and mastitis of sows and diarrhea of suckling piglets are often caused by the pathogens of Escherichia coli, Staphylococcus aureus, Salmonella cholerae suis, and Streptococcus agalactiae (5, 6), and these pathogens can be killed by many additives including nanzymes, organic acids, probiotics, herbs, and herb extracts under a certain concentration (7–11). Supplementation of Chinese medicine additives or Chinese medicine extracts to sows has effects in eliminating or alleviating metritis, vaginitis, and mastitis of sows and reducing diarrhea of suckling piglets (12–14), but the palatability of some untreated Chinese medicine additives or Chinese medicine extracts is not favorable owing to their bitter taste and feeding these additives or extracts directly to animals will decrease their feed intake. In addition, a large amount of residues will be produced and discarded during the production of Chinese medicine extracts, and the discarded residues will pollute the environment (15). The solid-state fermentation of compound Chinese medicine instead of extraction has many advantages including the better palatability of Chinese medicine additives and the less environmental pollution of Chinese medicine residues. The purpose of this study is to develop a fermented compound Chinese medicine feed additive formula by the in vitro antibacterial experiment and the identification of differential metabolites.

MATERIALS AND METHODS

Formula of Compound Chinese Medicine Feed Additives

According to the components and pharmacological characteristics of traditional Chinese medicines, the following traditional Chinese medicines were selected to compose three compound Chinese medicine feed additives. Compound Chinese medicine feed additive A comprised 20 parts of Houttuynia cordata, 23 parts of Folium artemisiae argyi, 40 parts of Thymifolious euphorbia herb, 8 parts of Cowherb seed, 25 parts of Potentilla discolor, 45 parts of Acalypha wilkesiana, 10 parts of sugar, 26 parts of wheat, 15 parts of soybean meal, 0.03 parts of Aspergillus niger, and 1.5 parts of yeast. Compound Chinese medicine feed additive B comprised 20 parts of Houttuynia cordata, 15 parts of Folium artemisiae argyi, 40 parts of Thymifolious euphorbia herb, 25 parts of Potentilla discolor, 45 parts of Motherwort, 14 parts of Licorice, 18 parts of sugar, 8 parts of wheat, 8 parts of soybean meal, 0.05 parts of Aspergillus niger, and 1.0 parts of yeast. Compound Chinese medicine feed additive C comprised 25 parts of Folium artemisiae argyi, 12 parts of Cowherb seed, 30 parts of Potentilla discolor, 25 parts of Thymifolious euphorbia herb, 30 parts of Acalypha wilkesiana, 25 parts of sugar, 10 parts of soybean meal, 0.02 parts of Aspergillus niger, and 0.7 parts of yeast. Traditional Chinese medicines, wheat and soybean meal were ground into powder using a pulverizer to pass through 80-mesh sieves.

Solid-State Fermentation of Compound Chinese Medicine Feed Additives

Tap water was firstly weighted at a ratio of 1:1 according to the weight of compound Chinese medicine feed additive and heated to 40°C to dissolve sugar, then Aspergillus niger and yeast were activated in this sugar solution for 30 min to produce a kind of fermentation liquid. The compound Chinese medicine feed additive was mixed with fermentation liquid, packed with plastic bags, and put into an oven for fermentation at 33°C for 36 h. The fermented additives were taken out and packed by vacuum sealing and stored at room temperature for 15 days.

Preparation of Concentrated Liquid of Fermented Compound Traditional Chinese Medicine Feed Additive

Fifty gram of each fermented compound traditional Chinese medicine feed additive was soaked with 500 ml distilled water in a beaker for 1 h; then, the liquid mixture in the beaker was heated to boil and kept boiling for 1 h and filtered with 8 layers of gauze. The filter liquor was transferred into a glass cup, and the filter residue was washed into the beaker and boiled with 300 ml distilled water for 1 h; later, the mixture was filtered again. The twice-filtered liquors were mixed together and concentrated to 25 ml in an oven at 65°C with a final concentration of 2 g/ml; the concentrated liquor was sterilized by high-pressure steam and stored at −20°C for subsequent tests.

Preparation of Bacterial Solution

Streptococcus agalactiae (GDMCC 1.768), Escherichia coli (GDMCC 1.176), Staphylococcus aureus (GDMCC 1.174), and Salmonella cholerae suis (GDMCC 1.163) were purchased from Guangdong Microbial Culture Collection Center. 0.3 ml brain heart infusion broth (BHI) broth was pipetted into the lyophilized tube containing Streptococcus agalactiae, then the tube was vortexed gently until the strain powder was completely dissolved; the suspension was pipetted into 5 ml BHI broth and cultured in an incubator at 37°C for 48 h. 0.3 ml Lennox broth (LB) was pipetted into the lyophilized tubes containing Escherichia coli, Staphylococcus aureus, and Salmonella cholerae suis; respectively, all tubes were vortexed gently until the strain powder was completely dissolved, then the suspension was respectively pipetted into 5 ml LB broth and cultured in an incubator at 37°C for 24 h. The optical density (OD) value of bacterial solution
was measured at 660 nm to reach a final concentration of $1.5 \times 10^8$ CFU/ml.

**In vitro Antibacterial Test**

The tryptone soybean agar (TSA) was poured into the petri dishes; after agar solidification, a total of 0.1 µl Escherichia coli suspension (Salmonella cholerae suis or Staphylococcus aureus suspension was also spread according to this method) was uniformly spread on the surface of agar and three Oxford cups (7.8 * 6 * 10 mm) marked A, B, and C were placed on the agar medium in each petri dish. Two-hundred microliter of concentrated liquor A, B, or C was added to the corresponding Oxford cup; each strain had 3 replicates. All petri dishes were incubated at 37°C for 18 h and then taken out for the measurement of diameter of bacteriostatic circles. The blood culture medium was kept at 37°C for 18 h and then taken out for the measurement of diameters of bacterial circles. The blood culture medium was prepared to measure the abilities of concentrated liquor A, B, and C against the growth of Streptococcus agalactiae with the above method. Among the three concentrated liquors, the one with the best bacteriostatic effects against Streptococcus agalactiae, Escherichia coli, Staphylococcus aureus, and Salmonella cholerae suis was selected to determine its minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC).

**MIC and MBC Determination**

The double dilution method was used to determine the MIC. The selected concentrated liquor was successively diluted with LB broth (for Escherichia coli, Staphylococcus aureus, and Salmonella cholerae suis) or with BHI broth (for Streptococcus agalactiae) to give concentrations ranging from 1 to 0.0078125 g/ml in 8 culture tubes, and the ninth tube was only added with 2 ml LB broth as the positive control. Fifty microliter of bacteria solution was added into each tube, and all tubes were incubated for 18 h at 37°C. The lowest concentration of the selected concentrated liquor that caused a visible inhibitory effect was defined as the MIC. The MBC was determined by incubating 10-µl samples from each tube with an inhibitory effect on plates with TSA (for Escherichia coli, Staphylococcus aureus, and Salmonella cholerae suis) or with blood culture medium (for Streptococcus agalactiae) at 37°C for 18 h, with the lowest concentration of sample with no visible sign of growth determined as the MBC. All experiments were conducted in three replicates.

**UHPLC-QE-MS-Based Untargeted Metabolomics**

Metabolomics was applied using 1,290 ultra-high-performance liquid chromatography (Agilent, CA, USA) coupled with Q Exactive focus MS/MS (Thermo Fisher Scientific, Waltham, MA, USA). Chromatographic separations were performed using a Waters ACQUITY system equipped with an ACQUITY UPLC BEH C18 column (1.7 µm, 2.1 × 100 mm). The mobile phase consisted of 0.1% formic acid water (A) and 0.1% formic acid acetonitrile (B) at the flow rate of 0.5 ml/min, and the injection volume was 4 µl. The gradient program was as follows: 85–25% B (0–11.0 min), 25–2% B (11.0–12.0 min), 2–2% B (12.0–14.0 min), 2–85% B (14.0–14.1 min), 85–85% B (14.1–15.0 min), and 85–8% B (15.0–16.0 min). The ESI source was applied to analyze the chemical composition in both positive and negative ion modes with full scan/ddMS2. The MS parameters were set as follows: the scan range was 50–1,000 m/z, the spray voltages were set at 4.0 and 3.6 kV in positive and negative modes, respectively, sheath gas was 35 arb, auxiliary gas was 10 arb, the capillary temperature was 400°C, the maximum injection time for MS1 and ddMS2 was 100 and 45 ms, respectively, and the resolutions for MS1 and ddMS2 were 70,000 and 17,500, respectively; putative molecules of interest were fragmented using three different collision energies (10, 20, and 40 eV).

**Multivariate Statistical Analysis and Metabolite Identification**

Raw data of UHPLC-QE-MS were processed using the XCMS online platform, and the qualified data were uploaded to SIMCA-P (Version 16.0.2, Sartorius Stedim Data Analytics AB, Umea, Sweden) for multivariate statistical analysis. Partial least-square-discriminate analysis (PLS-DA) and orthogonal partial least-square-discriminate analysis (OPLS-DA) were performed to find out the metabolic distinction. The variable importance of projection (VIP) values was used to characterize the contributions of the metabolites to the change rates of Y variety in OPLS-DA, and metabolites that meet these criteria including MS2 score > 0.80, VIP > 1.0, and p < 0.05 were selected as the differential variables; metabolite identification was performed by searching the in-house database and web databases (METLIN, HMDB, PubChem, and ChemSpider).

**Network Analysis of Targeted Differentially Metabolites**

To further investigate the mechanism of targeted differential metabolites, the network pharmacology approach was introduced to uncover the related pathways, compounds, enzymes, and reactions. Compounds with MS2 score > 0.80, VIP > 1.0, fold change > 1, and p < 0.05 were selected as the target differential metabolites and used to construct the network with FELLA R package (16). The nodes in the network were compounds, enzymes, pathways, modules, and reactions, and the relationship between them was represented by the lines between the nodes.

**Statistical Analysis**

Statistical analysis was performed by SPSS 17.0 (version 17.0, USA), comparisons between two groups were made with Student’s t-test; the value at p < 0.05 was considered as significance threshold, and the results were presented as mean ± SE.

**RESULTS**

**In vitro Bacteriostatic Effect of Different Fermented Compound Chinese Medicine Feed Additives**

The abilities of additives A, B, and C in inhibiting the growth of Streptococcus agalactiae, Escherichia coli, Staphylococcus aureus, and Salmonella cholerae suis were different and ranked as follows: A > C > B. Results in Figure 1 and Table 1 indicated that
additive A was the most effective in inhibiting the growth of *Staphylococcus aureus* but had the worst effect in preventing the growth of *Streptococcus agalactiae*, additive B had no bacteriostatic effect, and additive C had the ability in controlling the growth of *Streptococcus agalactiae*, *Staphylococcus aureus*, and *Salmonella cholerae suis* but had no bacteriostatic effect on *Escherichia coli*.

**Metabolic Network Analyses**

Network analysis was conducted in order to reveal the molecular network and mechanism of the interaction of the KEGG pathways with related compounds, enzymes, modules, and reactions. Twenty-three differential compounds were mapped with the KEGG database, and only five compounds (guanine-C00242, eriodictyol-C05631, kaempferide-C10098, threonic acid-C01620, and sinapine-C00933) indicated as green square in **Figure 2** were successfully mapped onto 5 KEGG metabolic pathways (purine metabolism-osa00230, flavonoid biosynthesis-osa00941, flavone and flavonol biosynthesis-osa00944, ascorbate and aldarate metabolism-osa00053, phenylpropanoid biosynthesis-osa00940). **Figure 2** shows that guanine, eriodictyol, kaempferide, threonic acid, and sinapine can be converted to the following compounds via the related enzymes and reactions: D-glucose, ascorbate, choline, D-ribose, oxalate, deoxyguanosine, xanthine, guanosine, sinapate, alpha-D-ribose 1-phosphate, 2-deoxy-D-ribose 1-phosphate, 1-O-sinapoyl-beta-D-glucose, 3-dehydro-L-threonate, kaempferol, homoeriodictyol, and eriodictyol chalcone.

**DISCUSSION**

Previous studies indicated that compounds listed in **Table 3** have bacteriostatic and/or bactericidal effects. Ellagic acid has strong inhibitory effects on *Staphylococcus aureus*, *Salmonella cholerae suis*, *Escherichia coli*, *Streptococcus*, and *Bacillus cereus* (17, 18). Purine and amino acids can inhibit the growth of bacteria in the form of riboswitches (a kind of RNA sequences that can bind...
to small molecular ligands and regulate gene expression, which can regulate the corresponding downstream gene expression after binding to purine and amino acids and other ligands), so as to achieve the antibacterial and bactericidal effects (19–21). Camphor can inhibit the growth of Salmonella cholerae suis and help animals to excrete toxins (22), while sinapine can inhibit the growth of Escherichia coli (23), 5,7-Dihydroxy-2-(4-hydroxyphenyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-6-(3,4,5-trihydroxyoxan-2-yl)chromen-4-one named as isoaxifota glycoside has inhibitory effects on Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis (24). Farrerol can inhibit the growth of Staphylococcus aureus (25); however, pyrogallol and demethylwedelolactone (norwedelide) not only can inhibit the growth of Staphylococcus aureus but also can prevent the growth of Escherichia coli and Salmonella (26, 27). Kaempferide, gallic acid, and taxifolin have good antibacterial effects on Staphylococcus aureus, Escherichia coli, dysentery bacilli, Pseudomonas aeruginosa, and Streptococcus (28–30). Ethyl gallate can inhibit the growth of Staphylococcus aureus and Escherichia coli (31, 32). Eriodictyol and inositol have good inhibitory effects on Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa (33, 34). Trihydroxyflavanone, asiatic acid, and isorhamnetin have good inhibitory or killing effects on Shigella dysentery bacteria, Salmonella, Streptococcus, Staphylococcus aureus, and Escherichia coli (35–37). These plant-derived active ingredients exert bacteriostatic and bactericidal effects through inhibiting the production of extracellular polymers (EPS), reducing bacterial adhesion, destroying the integrity and permeability of bacterial cell membrane.

### Table 2: MIC and MBC of fermented compound Chinese medicine feed additive A, g/ml.

| Concentrated liquor | Escherichia coli | Salmonella cholerae suis | Staphylococcus aureus | Streptococcus agalactiae |
|---------------------|-----------------|-------------------------|----------------------|-------------------------|
|                     | MIC         | MBC         | MIC              | MBC                    | MIC              | MBC              |
| A                   | 0.1250      | 0.2500      | 0.1250           | 0.2500                 | 0.0625          | 0.1250           | 0.1250           | 0.2500                 |

### Table 3: Information of differential metabolites with fold change (A/B) larger than 1.

| MS 2 name         | MS2 score | Compound A     | Compound B     | Fold change (A/B) | VIP  | p-value |
|-------------------|-----------|----------------|----------------|-------------------|------|---------|
| **Positive ion model** |           |                |                |                   |      |         |
| Ellagic acid      | 1.00      | 89970.65 ± 2047.27 | 6.03 ± 0.49  | 14920.51          | 1.44 | 0.048   |
| Guanine           | 1.00      | 893248.98 ± 12338.31 | 630877.16 ± 30348.84 | 1.42 | 1.41 | 0.001   |
| Camphor           | 0.97      | 165777.89 ± 17351.72 | 95213.63 ± 7517.58 | 1.74 | 1.30 | 0.020   |
| L-Valine          | 0.96      | 828283.61 ± 991023.05 | 4722270.50 ± 194648.71 | 1.75 | 1.30 | 0.024   |
| Sinapine          | 0.94      | 84351.79 ± 15192.09 | 25909.49 ± 4472.36 | 3.26 | 1.33 | 0.021   |
| Dipropylphthalate | 0.94      | 16261.57 ± 3902.65 | 3521.70 ± 1481.38 | 4.62 | 1.21 | 0.038   |
| 3-Hydroxy-5-isopropylidene-3,8-dimethyl-2,3,3a,4,5,8a-hexahydro-6(1H)-azulenone | 0.92 | 14268.67 ± 1464.43 | 956.23 ± 86.74 | 14.92 | 1.43 | 0.012   |
| 5,7-Dihydroxy-2-(4-hydroxyphenyl)-8-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-6-(3,4,5-trihydroxyoxan-2-yl)chromen-4-one | 0.92 | 95382.59 ± 7467.40 | 57754.10 ± 484.49 | 1.66 | 1.38 | 0.037   |
| Acetylcholine     | 0.91      | 4467186.16 ± 430688.27 | 47437.4 ± 4997.85 | 94.17 | 1.44 | 0.009   |
| Farrerol          | 0.81      | 91502.75 ± 10528.55 | 41296.36 ± 4047.05 | 2.22 | 1.37 | 0.011   |
| **Negative ion model** |           |                |                |                   |      |         |
| Pyrogallol        | 1.00      | 217175.34 ± 26949.40 | 85161.91 ± 7780.19 | 2.55 | 1.12 | 0.047   |
| Ethyl gallate     | 0.99      | 15482400.23 ± 2866182.97 | 49027.25 ± 4807.40 | 315.79 | 1.42 | 0.033   |
| Demethylwedelolactone | 0.98   | 178662.97 ± 15761.08 | 55273.17 ± 12557.93 | 3.23 | 1.32 | 0.004   |
| Methyl gallate    | 0.98      | 334131.77 ± 26014.26 | 3559.89 ± 977.21 | 93.86 | 1.21 | 0.006   |
| Kaempferide       | 0.98      | 386085.28 ± 48610.66 | 238296.59 ± 10102.16 | 1.62 | 1.24 | 0.041   |
| Gallic acid       | 0.98      | 17732911.31 ± 246965.79 | 63766.36 ± 4747.67 | 278.09 | 1.42 | 0.000   |
| Eriodictyol       | 0.92      | 408383.73 ± 16484.25 | 220608.65 ± 11549.24 | 1.85 | 1.39 | 0.001   |
| Threonic acid     | 0.92      | 1163675.16 ± 61626.38 | 539744.37 ± 78673.13 | 2.16 | 1.32 | 0.003   |
| Inositol          | 0.86      | 1927229.94 ± 103570.35 | 1419620.73 ± 40982.28 | 1.36 | 1.33 | 0.010   |
| 3′,4′,7-Trihydroxyflavanone | 0.85 | 5546.82 ± 981.38 | 2073.68 ± 610.07 | 2.67 | 1.21 | 0.040   |
| Taxifolin         | 0.84      | 73540.26 ± 12851.85 | 15961.30 ± 2362.12 | 4.61 | 1.36 | 0.012   |
| Asiatic acid      | 0.84      | 25611.49 ± 3923.63 | 1894.61 ± 459.78 | 13.52 | 1.38 | 0.025   |
| Isorhamnetin      | 0.81      | 204543.52 ± 25406.85 | 48807.20 ± 2097.82 | 4.37 | 1.40 | 0.024   |
FIGURE 2 | The compound–reaction–enzyme–pathway networks of the targeted metabolites. Compounds: C00031 (D-glucose), C00072 (ascorbate), C00114 (choline), C00121 (D-ribose), C00209 (oxalate), C00242 (guanine), C00330 (deoxyguanosine), C00332 (sinapine), C01175 (1-O-sinapoyl-beta-D-glucose), C01620 (threonate), C02084 (3-dehydro-L-threonate), C05631 (eriodictyol), C05903 (kaempferol), C07956 (homoeriodictyol), C10098 (kaempferide), C15525 (eriodictyol chalcone). Reactions: R00068 (L-ascorbate:oxygen oxidoreductase), R00190 (AMP:phospho-D-ribosyltransferase), R00273 (oxalate:oxygen oxidoreductase), R00466 (glyoxylate:oxygen oxidoreductase), R00522 (oxalate carboxy-lyase), R00644 (L-ascorbate:hydrogen-peroxide oxidoreductase), R00646 (ascorbate + oxygen + H2O <= threonate + oxalate), R01021 (ATP:choline phosphotransferase), R01022 (choline:oxygen 1-oxidoreductase), R01025 (choline:acceptor 1-oxidoreductase), R01132 (IMP:phospho-D-ribosyltransferase), R01227 (guanosine 5′-monophosphate phosphohydrolase), R01228 (ATP:guanosine 5′-phosphotransferase), R01229 (GMP:phospho-D-ribosyltransferase), R01310 (phosphatidylcholine phosphatidohydrolase), R01559 (succinyl-CoA:CO-phosphotransferase), R01676 (guanine aminohydrolase), R01677 (guanosine ribohydrolase), R01969 (deoxyguanosine:orthophosphatidyltransferase), R02142 (IMP:pyrophosphate phosphoribosyltransferase), R02147 (guanosine:phosphate alpha-D-ribosyltransferase), R02221 (sinapate:CoA ligase (AMP-forming)), R02379 (S-adenosyl-L-methionine:3,4-dihydroxy-trans-caffeoyl-coenzyme), R02380 (UDP-glucose:sinapate D-glucohydrolase), R02381 (sinapylcholine sinapohydrolase), R02442 (6-naringenin:[reduced NADP+—hemoprotein reductase], R03075 (1-O-(4-hydroxy-3,5-dimethoxycinnamoyl),beta-dimethoxycinnamoyl), R03126 (dihydroflavonol-2-oxidoreductase:oxygen oxidoreductase), R03590 (flavanone,2-oxidoreductase:oxygen oxidoreductase), R03640 (flavanone,2-oxidoreductase:oxygen oxidoreductase), R03733 (L-threonate:NAD+ 3-oxidoreductase), R04901 (2S-flavonone-4-ol:NADP+ 4-oxidoreductase), R04902 (eriodictyol:[reduced NADPH—hemoprotein reductase], R05794 (CDP-diacetylgluceral:choline O-phosphatidyltransferase), R05980 (GlucoseGlCNAC2-[protein] 3-alpha-glucopyranosyltransferase), R05981 (GlucoseGlCNAC2-[protein] 3-alpha-glucopyranosyltransferase), R05982 (GlucoseMan4GlCNAC2-[protein] 3-alpha-glucopyranosyltransferase).
inactivating enzymes of bacteria, changing cell metabolism, blocking nucleic acid synthesis, and enhancing animal immunity (38, 39). Figure 2 shows that the differential metabolites which have been mapped onto metabolic pathways can be converted to D-glucose and 2-deoxy-D-ribose-1-phosphate, exposure to high concentration of glucose exerted bacteriostatic or bactericidal effects by destroying ribosome assembly of bacteria (40), and 2-deoxy-d-ribose-1-phosphate can achieve the purpose of bacteriostasis by inhibiting the synthesis of bacterial nucleic acid (41).

Results of this experiment showed that fermented compound Chinese medicine feed additive A had significantly higher concentrations of ellagic acid, guanine, camphor, L-valine, sinapine, dipropylphthalate, 3-hydroxy-5-isopropylidene-3,8-dimethyl-2,3,3a,4,5,8a-hexahydro-6(1H)-azulenone, and 2-deoxy-D-ribose-1-phosphate can achieve the purpose of bacteriostasis by inhibiting the synthesis of bacterial nucleic acid (41).

CONCLUSIONS

Additive A had the strongest ability to inhibit the growth of Staphylococcus aureus, Salmonella cholerae suis, Escherichia coli, and Streptococcus agalactiae; the mixture composed of 23 active components in fermented compound Chinese medicine feed additive A exerted bacteriostatic and/or bactericidal effects on the tested pathogens. The sensitivity of these four bacteria to fermented compound traditional Chinese medicine feed additive A is ranked as Staphylococcus aureus > Salmonella cholerae suis > Escherichia coli > Streptococcus agalactiae.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

AUTHOR CONTRIBUTIONS

YH and WL: concept, experimental design, and manuscript preparation. WZ, HH, and YC: investigation. WZ and HW: data analysis. All authors have read and agreed to the published version of the manuscript.

FUNDING

This work was supported by the Key Research and Development Plan of Jiangxi Province (2019BBFL60021).

REFERENCES

1. Mauch C, Bilkei G. The influence of prepartal bacteriuria on the reproductive performance of the sow. Dtsch Tierarztl Wochenschr. (2004) 111:166–9.
2. Kaiser M, Jacobsen M, Andersen PH, Babko P, Cerón JJ, Dahl J, et al. Inflammatory markers before and after farrowing in healthy sows and in sows affected with postpartum dysgalactia syndrome. BMC Vet Res. (2018) 14:83. doi: 10.1186/s12917-018-1382-7
3. Hirsch AC, Philipp H, Kleemann R. Investigation on the efficacy of meloxicam in sows with mastitis-metritis-agalactia syndrome. J Vet Pharmacol Ther. (2003) 26:355–60. doi: 10.1046/j.1365-2885.2003.00524.x
4. Alexopoulos C, Fihenakis GC, Burriel A, Bouritsi-Hatzopoulos E, Kritas SK, Shiraki A, et al. The effects of the periodical use of in-feed chlortetracycline on the reproductive performance of gilts and sows of a commercial pig farm with a history of clinical and subclinical viral and bacterial infections. Reprod Domest Anim. (2003) 38:187–92. doi: 10.1046/j.1439-0531.2003.00415.x
5. Kemper N, Bardeleb D, Lehmann I, Jerjets I, Looft H, Preisler R. The role of bacterial pathogens in coliform mastitis in sows. Berl Munch Tierarztl Wochenschr. (2013) 126:130–6. doi: 10.2376/0005-9366-126-130
6. Rodríguez PYDLF, Martin LOM, Muñoz EC, Imberechts H, Butaye P, Goddeeris BM, et al. Several enteropathogens are circulating in suckling and newly weaned piglets suffering from diarrhea in the province of Villa Clara, Cuba. Trop Anim Health Prod. (2013) 45:345–40. doi: 10.1007/s11250-012-0236-8
7. Shi SR, Wu S, Shen YR, Zhang S, Xiao YQ, He X, et al. Iron oxide nanzyme suppresses intracellular Salmonella enteritidis growth and alleviates infection in vivo. Theranostics. (2018) 8:6149–62. doi: 10.7150/thno.29303
8. Xiao YQ, Zhang S, Tong HB, Shi SR. Comprehensive evaluation of the role of soy and isoflavone supplementation in humans and animals over the past two decades. Phytother Res. (2018) 32:384–94. doi: 10.1002/ptr.5966
9. Zhang S, Zhong G, Shao D, Wang Q, Hu Y, Wu TX, et al. Dietary supplementation with Bacillus subtilis promotes growth performance of

Zou et al. Fermented Chinese Medicine and Antibacteria

FIGURE 2 | eriodictyol, R07992 (homeodictyol chalcone -> homoedictyol), R08007 (UDP-alpha-D-glucose:2′,3,4,4′,6′-pentahydroxy heptanal), R08012 (eriodictyol -> homoedictyol), R08031 (eriodictyol chalcone -> homoedictyol chalcone), R08557 (choline + NAD+ -> betaine aldehyde + NADH), R08558 (choline + NADP+ -> betaine aldehyde + NADPH), R09802 (UDP-L-rhamnose:kaempferol-3-O-rhamnosyltransferase), R10261 (1-O-sinapoyl-beta-D-glucose:cytidin-3-O-beta-D-glucoside), R10296 (1-O-sinapoyl-beta-D-glucose:galactosidin-3-O- malonylgalactoside), R10299 (1-O-sinapoyl-beta-D-glucose:delphinidin-3-O- beta-D-glucoside), R12279 (eriodictyol,[reduced NADPH→ hemoprotein reductase]. Enzymes: 1.1.99.1 (choline dehydrogenase), 1.10.3.3 (L-aspartate oxidase), 1.14.11.9 (flavonoid 3-dioxogenase), 1.14.1.82 (flavonoid 3′-monooxygenase), 1.14.15.7 (choline monooxygenase), 1.14.19.76 (flavone synthase II), 1.14.20.6 (flavonol synthase), 1.2.1.68 (coniferyl-aldehyde dehydrogenase), 1.6.5.4 [monodehydroascorbate reductase (NADH)], 2.4.2.7 (adenine phosphoribosyltransferase), 2.4.2.8 (hypoxanthine phosphoribosyltransferase), 2.7.1.32 (choline kinase), 3.1.3.75 (phosphoethanolamine/phosphocholine phosphatase). Pathways: osa00053 (ascorbate and aldarate metabolism), osa00230 (purine metabolism), osa00940 (phenylpropanoid biosynthesis), osa00941 (flavonoid biosynthesis), osa00944 (flavone and flavonol biosynthesis).
